Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial.

IF 1.6 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Phlebology Pub Date : 2023-10-01 Epub Date: 2023-07-30 DOI:10.1177/02683555231191969

Oksana V Bukina, Aleksandr A Sinitsyn, Oksana I Efremova, Andrey V Pelevin

{"title":"Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial.","authors":"Oksana V Bukina, Aleksandr A Sinitsyn, Oksana I Efremova, Andrey V Pelevin","doi":"10.1177/02683555231191969","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS).Methods: Women aged 18-70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5).Results: A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25-4), STS 0.1% (3, 1.25-4), and STS 0.15% (4, 2-4) groups than in the HG group (4, 3-5) after 56 days, p = .00002.Conclusion: Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS.Trial registration: ClinicalTrials.gov NCT04132323.","PeriodicalId":20139,"journal":{"name":"Phlebology","volume":" ","pages":"622-627"},"PeriodicalIF":1.6000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02683555231191969","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS).

Methods: Women aged 18-70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5).

Results: A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25-4), STS 0.1% (3, 1.25-4), and STS 0.15% (4, 2-4) groups than in the HG group (4, 3-5) after 56 days, p = .00002.

Conclusion: Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS.

Trial registration: ClinicalTrials.gov NCT04132323.

查看原文本刊更多论文

低浓度十四烷基硫酸钠和高渗葡萄糖溶液治疗毛细血管扩张症：一项前瞻性随机临床试验。

目的：本研究旨在比较高渗葡萄糖（HG）和不同浓度的十四烷基硫酸钠（STS）硬化治疗后毛细血管扩张症的消失。方法：纳入18-70岁患有毛细血管扩张症的女性。主要疗效终点是毛细血管扩张消失。使用六分制（从0到5）评估船只的清理情况。结果：共有116名女性完成了8周的随访：HG75%组、STS 0.05%组、STS 0.1%组和STS 0.15%组分别为31名、27名、25名和33名。56天后，STS 0.05%（3,0.25-4）、STS 0.1%（3,1.25-4）和STS 0.15%（4,2-4）组的静脉消失中位评分显著低于HG组（4,3-5），p=0.0002。结论：75%HG硬化治疗毛细血管扩张症的效果明显好于低浓度STS。试验注册：ClinicalTrials.gov NCT04132323。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phlebology 医学-外周血管病

CiteScore

3.30

自引率

11.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555